Indaptus Therapeutics (INDP) Competitors $4.61 -0.79 (-14.63%) Closing price 04:00 PM EasternExtended Trading$3.84 -0.77 (-16.70%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock INDP vs. PMN, THAR, CVKD, CASI, AKTX, DARE, TENX, RNTX, TRIB, and MIRAShould you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include Promis Neurosciences (PMN), Tharimmune (THAR), Cadrenal Therapeutics (CVKD), CASI Pharmaceuticals (CASI), Akari Therapeutics (AKTX), Dare Bioscience (DARE), Tenax Therapeutics (TENX), Rein Therapeutics (RNTX), Trinity Biotech (TRIB), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry. Indaptus Therapeutics vs. Its Competitors Promis Neurosciences Tharimmune Cadrenal Therapeutics CASI Pharmaceuticals Akari Therapeutics Dare Bioscience Tenax Therapeutics Rein Therapeutics Trinity Biotech MIRA Pharmaceuticals Indaptus Therapeutics (NASDAQ:INDP) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership. Which has higher valuation & earnings, INDP or PMN? Promis Neurosciences is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndaptus TherapeuticsN/AN/A-$15.02M-$37.66-0.12Promis NeurosciencesN/AN/A$2.78M-$0.21-2.05 Does the media prefer INDP or PMN? In the previous week, Indaptus Therapeutics had 3 more articles in the media than Promis Neurosciences. MarketBeat recorded 4 mentions for Indaptus Therapeutics and 1 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.00 beat Indaptus Therapeutics' score of -0.50 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indaptus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Promis Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in INDP or PMN? 7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 20.8% of Indaptus Therapeutics shares are owned by insiders. Comparatively, 6.1% of Promis Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts recommend INDP or PMN? Indaptus Therapeutics presently has a consensus price target of $238.00, indicating a potential upside of 5,062.69%. Promis Neurosciences has a consensus price target of $4.33, indicating a potential upside of 907.75%. Given Indaptus Therapeutics' higher probable upside, analysts plainly believe Indaptus Therapeutics is more favorable than Promis Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Promis Neurosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, INDP or PMN? Indaptus Therapeutics has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Promis Neurosciences has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500. Is INDP or PMN more profitable? Promis Neurosciences' return on equity of -266.69% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Indaptus TherapeuticsN/A -612.59% -243.78% Promis Neurosciences N/A -266.69%-131.59% SummaryPromis Neurosciences beats Indaptus Therapeutics on 7 of the 12 factors compared between the two stocks. Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INDP vs. The Competition Export to ExcelMetricIndaptus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.98M$2.55B$5.75B$9.85BDividend YieldN/A49.35%6.67%4.51%P/E Ratio-0.1222.9078.4326.42Price / SalesN/A714.55546.94119.09Price / CashN/A169.7737.0558.92Price / Book0.435.3910.916.06Net Income-$15.02M$32.95M$3.29B$266.28M7 Day Performance-27.86%0.48%0.01%-0.76%1 Month Performance-36.85%6.61%7.06%3.83%1 Year Performance-88.65%-0.50%50.09%24.39% Indaptus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INDPIndaptus Therapeutics2.5185 of 5 stars$4.61-14.6%$238.00+5,062.7%-87.7%$5.98MN/A-0.126News CoverageShort Interest ↑High Trading VolumePMNPromis Neurosciences2.8113 of 5 stars$0.55+2.7%$4.33+689.3%-64.9%$28.44MN/A-2.615News CoverageTHARTharimmune2.783 of 5 stars$6.11-20.8%$17.00+178.2%+67.4%$28.35MN/A-1.002Short Interest ↑High Trading VolumeCVKDCadrenal Therapeutics3.4189 of 5 stars$13.75+11.6%$32.00+132.7%+61.9%$28.19MN/A-1.554News CoverageShort Interest ↓Gap UpCASICASI Pharmaceuticals3.6813 of 5 stars$2.29-5.8%$4.00+74.7%-64.2%$28.17M$28.54M-0.90180Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionAKTXAkari Therapeutics3.3804 of 5 stars$0.86-2.8%$5.00+481.4%-82.8%$27.68MN/A0.009News CoverageShort Interest ↑High Trading VolumeDAREDare Bioscience1.9826 of 5 stars$2.04-1.9%$12.00+488.2%-42.8%$27.50M$10K-0.9530News CoverageAnalyst UpgradeGap UpTENXTenax Therapeutics1.3616 of 5 stars$5.90-0.3%$17.00+188.1%+56.0%$26.90MN/A-6.419RNTXRein TherapeuticsN/A$1.15-2.5%N/AN/A$26.80MN/A-0.439News CoveragePositive NewsGap UpTRIBTrinity Biotech0.6702 of 5 stars$1.47-5.2%N/A-85.2%$26.53M$61.56M-0.50480Short Interest ↑MIRAMIRA Pharmaceuticals3.1756 of 5 stars$1.39-2.1%$17.00+1,123.0%-22.8%$26.51MN/A-2.842Short Interest ↓ Related Companies and Tools Related Companies PMN Alternatives THAR Alternatives CVKD Alternatives CASI Alternatives AKTX Alternatives DARE Alternatives TENX Alternatives RNTX Alternatives TRIB Alternatives MIRA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INDP) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
